Synopsis Uterine leiomyomas are the most common benign gynecologic condition, occurring in up to 70% of women. Ulipristal acetate is an orally administered selective progesterone receptor that acts to decrease bleeding and reduce leiomyoma size. Thus, to assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas was evaluated. This week’s “MED FACT” discusses a clinical trial from Obstetrics & Gynecology, “Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial”.
Authors: Simon, James, A et. al. Key Takeaways Ulipristal 5 mg & 10 mg was well tolerated in women with symptomatic uterine leiomyomas. Objective: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas…
